NCT02480374 2024-10-02
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Imunon
Phase 1 Completed
Clinical Trials
4 trialsNCT01489371 2019-03-12
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT00473954 2013-03-26
Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer
EGEN, Inc.
Phase 1 Completed
NCT00137865 2013-02-28
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
EGEN, Inc.
Phase 1 Terminated